Work Programme

The work programme features only submissions that have been scheduled for assessment over the coming 2/3 months.

Search for forthcoming assessment



Click the + symbols to view search results by BNF category.

Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
There are currently no submissions for this category.
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
bivaluridin (Angiox) The Medicines Company 13.09.10 Full submission 12.07.10
anticoagulant in adult patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
dronedarone (Multaq) Sanofi-aventis Ltd 13.09.10 Full submission 12.07.10
for the treatment of atrial fibrillation
ranolazine (Ranexa) A Menarini Pharma UK SRL 13.12.10 Resubmission 11.10.10
Angina pectoris
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
agomelatine (Valdoxan) Servier 13.09.10 Resubmission 12.07.10
for the treatment of major depressive episodes in adults.
aripiprazole (Abilify) Bristol-Myers Squibb / Otsuka Pharmaceuticals 13.09.10 Abbreviated Submission
for the treatment of schizophrenia in adolescents
capsaicin (Qutenza) Astellas Pharma UK Ltd tbc Full submission tbc
peripheral neuropathic pain in non-diabetic adults
diclofenac 4% gel spray (Mobigel) Goldshield Pharmaceuticals Limited tbc Abbreviated Submission tbc
Local symptomatic relief of mild to moderate pain and inflammation
eslicarbazepine (Zebinix) Eisai Ltd. 08.11.10 Resubmission 13.09.10
As adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation
fentanyl pectin nasal spray (PecFent) Archimedes Pharma tbc Full submission tbc
Breakthrough pain in chronic cancer pain
levetiracetam (Keppra) UCB Pharma TBC Abbreviated Submission TBC
Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy
oxycodone injection (Oxynorm) Napp Pharmaceuticals Ltd 08.11.10 Full submission 13.09.10
for the treatment of moderate to severe pain in patients with cancer.
prilocaine (Prilotekal) Goldshield Group tbc Full submission tbc
Spinal anaesthesia
tapentadol hydrochloride (Palexia) Grunenthal Ltd 13.12.10 Full submission 11.10.10
Severe chronic pain
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
There are currently no submissions for this category.
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
denosumab (Prolia) Amgen 13.12.10 Full submission 11.10.10
Osteoporosis in postmenopausal women at increased risk of fractures and treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk fractures.
denosumab (Prolia) Amgen Uk & Ireland Ltd 13.12.10 Full submission 11.10.10
Osteoporosis in postmenopausal women
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
dexamethasone (Ozurdex) Allergan Ltd 13.12.10 Full submission 11.10.10
Macular oedema
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
There are currently no submissions for this category.
prucalopride (Prilotekal) Movetis UK Regus 13.12.10 Full submission 11.10.10
Chronic constipation in women
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
moxifloxacin (Avelox IV) Bayer Schering 13.12.10 Full submission 11.10.10
Community acquired pneumonia (CAP)
moxifloxacin hydrochloride solution for infusion (Avelox IV) Bayer Schering Ltd. 13.12.10 Full submission 11.10.10
For the treatment of community acquired infection (CAP)
valganciclovir (Valcyte) Roche tbc Full submission tbc
Prevention of cetomegalovirus (CMV) disease in CMV-negative patients who have received a solid organ transplant from CMV-positive donor
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
abarelix (Plenaxis) Speciality European Pharma (SEP tbc Full submission
Hormonal castration in patients with advanced or metastatic hormone-dependent prostate cancer, if androgen suppression is appropriate
buserelin acetate (Suprefact Depot) Sanofi-Aventis tbc Full submission
Advanced hormone-dependant prostatic carcinoma
docetaxel (Taxotere) Sanofi-Aventis tbc Abbreviated Submission tbc
1-vial Taxotere has been developed to offer a simplified one-step and time saving preparation while maintaining the original Taxotere formulation.
erlotinib (Tarceva) Roche tbc Full submission tbc
Non-small cell lung cancer NSCLC
gefitinib (Iressa) Astra Zeneca Ltd 13.12.10 Resubmission 11.10.10
Non-small cell lung cancer
histamine dihydrochloride (Ceplene) Meda Pharmaceuticals tbc Full submission tbc
Acute myeloid leukaemia in adults at first remission
imatinib (Glivec) Novartis Pharmaceuticals UK Ltd 13.09.10 Resubmission 12.07.10
adjuvant GIST treatment
pegylated interferon alfa 2b (Viraferon Peb) MSD tbc Full submission tbc
For the treatment of children and adolescents who have chronic hepatitis C, not previously treated
pemetrexed (Alimta) Eli Lilly & Company Ltd 11.10.10 Full submission 09.08.10
Non-small cell lung cancer
trabectedin (Yondelis) PharmaMar S.A 13.09.10 Full submission 12.07.10
for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
trabectedin (Yondelis) Pharma Mar 08.11.10 Resubmission 13.09.10
Soft tissue sarcoma
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
certolizumab pegol (Cimzia) UCB Pharma 11.10.10 Resubmission 09.08.10
Rheumatoid arthritis
febuxostat (Adenuric) Menarini Pharma UK SRL 13.09.10 Full submission 12.07.10
chronic hyperuricaemia in conditions where urate deposition has already occurred
glucosamine sulphate sodium chloride (Glusartel) HFA Healthcare Limited 08.11.10 Full submission 13.09.10
for the treatment of OA of the knee.
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
eculizumab (Soliris) Alexion Pharma UK Ltd. 08.11.10 Full submission 13.09.10
Paroxysmal nocurnal haemoglobinuria
ferric carboxymaltose (Ferinject) Vifor Pharmaceuticals tbc Resubmission tbc
Iron deficiency
filgrastim (Nivestim) Hospira UK Limited tbc Full submission tbc
Rreduction in the duration of neutropenia and the incidence of febrile neutropenia (FN) in patients treated with established cytotoxic chemotherapy for malignancy
lanthanum carbonate (Fosrenol) Shire Pharmaceuticals Ltd 11.10.10 Full submission 09.08.10
Hyperphosphataemia
pegfilgrastim (Neulasta) Amgen Ltd tbc Abbreviated Submission
Reduction in the duration of neutropenia
sevelamer carbonate (Renvela) Genzyme Therapeutics Ltd 11.10.10 Full submission 09.08.10
control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
sevelamer carbonate (Renvela) Genzyme Therapeutics Ltd 08.11.10 Full submission 09.08.10
Hyperphosphataemia
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
ethinylestradiol and levonorgestrel 3 (TriRegol) Consilient Health Ltd 11.10.10 Abbreviated Submission 09.08.10
oral contraceptive
ethinylestradiol 30mcg and levonorgestrel 150mcg (Rigevidon) Consilent Health Ltd 11.10.10 Abbreviated Submission 09.08.10
oral contraception
ethinylestradiol and desogestrel (Gedarel) Consilient Health Ltd 11.10.10 Abbreviated Submission 09.08.10
oral contraceptive
ethinylestradiol and gestodene (Millinette) Consilient Health Ltd 11.10.10 Abbreviated Submission 09.08.10
oral contraception
etonogestrel (Nexplanon) Merck Sharp & Dohme 13.12.10 Abbreviated Submission 11.10.10
Contraception
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
roflumilast (Daxas) Nycomed Ltd 11.10.10 Full submission 12.07.10
maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients
Drug Name Manufacturer Advice Due Date Submission Type Patient Interest Group Submission Deadline Date
tacrolimus (Modigraf) 0.2mg and 1mg granules Astellas Pharma Ltd TBC Abbreviated Submission TBC
For treatment of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressives
ustekinumab (Stelara) Janssen-Cilag Ltd tbc Abbreviated Submission tbc
severe plaque psoriasis